MNPRMNPRHealthcare · Biotechnology

MNPR Stock Forecast: Monopar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$71
−0.34% on the day

The 12 Wall Street analysts covering Monopar Therapeutics, Inc. hold a median 12-month price target of $130 — +83.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$481.6M
Ticker Nerd rank
61/ 100
Median analyst target
$130
Analysts covering
12
Revenue$0.0
Operating income−$6.6M
Net income−$5.3M
Free cash flow−$3.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
+2.2%
YTD
+8.5%
1Y
−12.1%
From 52W high
−42.8%
From 52W low
+41.3%
$50
$124
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Monopar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
61/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
85
Quality
77
Growth
57
Momentum
55
Revisions
53
Size
52
Accruals
46
Volatility
35
Issuance
34

Value (85): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MNPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26MNPRHigh $145Median $130Low $119

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $119Median $130High $145

The green dot is the last close — the median target sits +83.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026Morgan StanleyMaintainsOverweight$130 → $133
12 Nov 2026Cantor FitzgeraldUpgradeOverweight$119
11 Sept 2026BarclaysMaintainsOverweight$128 → $145
11 Sept 2026BarclaysMaintainsOverweight—
13 Aug 2026BarclaysMaintainsOverweight$125 → $128
13 Aug 2026BarclaysMaintainsOverweight—
13 Aug 2026Cantor FitzgeraldDowngradeNeutral—
13 Aug 2026Cantor FitzgeraldDowngradeNeutral$109 → $119
12 Aug 2026BTIGMaintainsBuy—
12 Aug 2026BTIGMaintainsBuy$117 → $133
22 July 2026HC Wainwright & Co.MaintainsBuy—
22 July 2026HC Wainwright & Co.MaintainsBuy$105 → $125
30 June 2026BTIGMaintainsBuy—
30 June 2026BTIGMaintainsBuy$104 → $117
29 June 2026HC Wainwright & Co.ReiteratesBuy—
29 June 2026HC Wainwright & Co.ReiteratesBuy$105
30 Mar 2026Chardan CapitalMaintainsBuy—
23 Feb 2026BTIGReiteratesBuy—
2 Feb 2026BTIGReiteratesBuy—
29 Jan 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MNPR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MNPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Monopar Therapeutics, Inc. returned −12.1% against +12.2% for the S&P 500, dividends included.

MNPR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26MNPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MNPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
4
Fundamentals

Monopar Therapeutics, Inc. (MNPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−38.8×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
3.8×

Cheaper than 24% of US stocks

EV / EBITDA
−21.1×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−15.3%

Higher than 33% of US stocks

Return on assets
−11.6%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Monopar Therapeutics, Inc. (MNPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Monopar Therapeutics, Inc. has a market value of $481.6M and an enterprise value of $352.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 6.7M.

  • Trailing P/E: −38.8×; forward P/E: −25.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Monopar Therapeutics, Inc. employs 22 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

MNPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNPRMonopar Therapeutics, Inc.$481.6M61
CAPRCapricor Therapeutics, Inc.$483.7M18
NGNENeurogene, Inc.$478.2M39
RGNXREGENXBIO, Inc.$472.8M63
MDXGMiMedx Group, Inc.$472.4M69
BLSMBlossomhill Therapeutics, Inc.$463.6M1
FENCFennec Pharmaceuticals, Inc.$463.6M95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Monopar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNPR news & analysis

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

GlobeNewsWire · 9 Nov 2026positive

Monopar announced that it presented baseline Phase 3 FoCus data on residual disease burden in treatment-experienced Wilson disease patients, along with molybdenum balance and long-term uric acid data for investigational ALXN1840, at AASLD – The Liver Meeting 2026.

Why it matters — The presentations provide updates on the patient profile and safety-related data being studied for Monopar’s investigational Wilson disease therapy.

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

GlobeNewsWire · 2 Nov 2026positive

Monopar announced that two abstracts on its investigational Wilson disease therapy ALXN1840 (tiomolibdate choline, TMC) will be presented at AASLD – The Liver Meeting 2026. The headline identifies the topics as Phase 3 FoCus baseline data and ALXN1840 molybdenum safety data.

Why it matters — The presentations will share clinical baseline and safety information on Monopar’s investigational Wilson disease therapy.

Monopar Appoints Jeffrey D. Kent, M.D.

GlobeNewsWire · 19 Aug 2026positive

Monopar Therapeutics announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, effective September 1, 2026. The company also reported that two abstracts on ALXN1840 (tiomolibdate choline), its late-stage Wilson disease candidate, were accepted for presentation at AASLD – The Liver Meeting 2026 in Denver.

Why it matters — MNPR watchers would note the new medical affairs leadership and the acceptance of abstracts on its late-stage Wilson disease candidate at a major hepatology conference, which highlight progress on the company's key development program.

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

Seeking Alpha · 18 Aug 2026positive

Monopar Therapeutics holds exclusive license rights to ALXN1840 for Wilson disease and continues radiotherapeutic development. The company is completing a rolling NDA submission for ALXN1840, which demonstrated statistically significant efficacy in phase 3 trials, presenting a potential catalyst for FDA approval and Priority Review Voucher upside.

Why it matters — A MNPR watcher would care because completion of the ALXN1840 rolling NDA submission and potential FDA approval represent a major upcoming milestone for the company's lead program.

FAQ

Frequently asked questions about MNPR stock

What is the MNPR stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Monopar Therapeutics, Inc. have a median 12-month price target of $130, with estimates ranging from $119 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNPR stock a buy right now?

Of the 12 analysts covering Monopar Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monopar Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNPR?

As at 17 Nov 2026, Monopar Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (85 of 100).

Will MNPR stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +83.6% from the last close, and Ticker Nerd's factor model ranks Monopar Therapeutics, Inc. 61 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNPR stock forecast for 2030?

No analyst covering Monopar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $119 to $145 over the next 12 months.

How has MNPR stock performed over the past year?

Monopar Therapeutics, Inc. returned -12.1% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Monopar Therapeutics, Inc. do?

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancer and rare diseases.

What is the latest news on MNPR?

The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates". Monopar Therapeutics announced its third-quarter 2026 financial results and provided business updates on November 12, 2026.

Company

About Monopar Therapeutics, Inc.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancer and rare diseases. Its current work centers on novel radiopharmaceuticals for oncology, antibody-based programs, and other proprietary therapies designed to address serious conditions with limited treatment options. The company’s pipeline includes candidates aimed at advanced cancers, such as soft tissue sarcoma and other hard-to-treat oncology settings, as well as a treatment program for Wilson disease, a rare genetic disorder. Monopar Therapeutics Inc. operates as a research-driven drug developer, advancing its assets through preclinical and clinical development rather than commercial product sales. Based in Wilmette, Illinois and founded in 2014, Monopar Therapeutics Inc. plays a specialized role in the healthcare market by pursuing innovative therapies for patients with significant unmet medical needs.

CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. · 22 employees · United States · https://www.monopartx.com